On 6 October 2014, a female Norwegian MSF worker tested positive for Ebola virus and was subsequently evacuated to Norway.[195] Norwegian authorities reported that they had been granted a dose of the experimental biopharmaceutical drug ZMAb, a variant of ZMapp.[196][197][198] ZMapp has previously been used on 3 Liberian health workers, of which 2 survived.[199] It was also used on 4 evacuated westerners, of which 3 survived.[200][201][202][203][204][205] A U.N. employee was evacuated to France in early November 2014 after contracting Ebola.[206]